Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin add-on versus metformin dose escalation in inadequately controlled type 2 diabetes on SGLT2 inhibitor plus low-dose metformin
ChiCTR2400090646Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cofrogliptin and metformin in type 2 diabetes mellitus (T2DM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change in glycated hemoglobin from baseline at 24 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
cofrogliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400090646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090646.